SG52789A1 - The human C3B/C4B receptor (cr1) - Google Patents

The human C3B/C4B receptor (cr1)

Info

Publication number
SG52789A1
SG52789A1 SG1996009545A SG1996009545A SG52789A1 SG 52789 A1 SG52789 A1 SG 52789A1 SG 1996009545 A SG1996009545 A SG 1996009545A SG 1996009545 A SG1996009545 A SG 1996009545A SG 52789 A1 SG52789 A1 SG 52789A1
Authority
SG
Singapore
Prior art keywords
fragments
expression
protein
secreted
proteins
Prior art date
Application number
SG1996009545A
Other languages
English (en)
Inventor
Douglas Fearon
Gerald R Carson
Henry C Marsh Jr
Lloyd B Klickstein
Michael F Concino
Savvas C Makrides
Stephen H Ip
Winnie W Wong
Original Assignee
T Cell Sciences Inc
Brigham & Womens Hospital
John Hopskins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc, Brigham & Womens Hospital, John Hopskins University filed Critical T Cell Sciences Inc
Publication of SG52789A1 publication Critical patent/SG52789A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Joining Of Building Structures In Genera (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG1996009545A 1988-04-01 1989-03-31 The human C3B/C4B receptor (cr1) SG52789A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17653288A 1988-04-01 1988-04-01
US41274589A 1989-09-26 1989-09-26

Publications (1)

Publication Number Publication Date
SG52789A1 true SG52789A1 (en) 1998-09-28

Family

ID=26872337

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996009545A SG52789A1 (en) 1988-04-01 1989-03-31 The human C3B/C4B receptor (cr1)

Country Status (14)

Country Link
EP (1) EP0411031B1 (es)
JP (1) JP3484189B2 (es)
CN (2) CN1092712C (es)
AT (1) ATE240973T1 (es)
CA (2) CA1340866C (es)
DE (1) DE68929466T2 (es)
DK (1) DK175699B1 (es)
ES (1) ES2014593A6 (es)
FI (2) FI106316B (es)
IL (1) IL89790A (es)
NO (1) NO315944B1 (es)
SG (1) SG52789A1 (es)
WO (1) WO1989009220A1 (es)
ZA (2) ZA892397B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
CN1491624A (zh) 1989-10-12 2004-04-28 ��������ķ������ 经修饰的生物材料
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DK0574402T3 (da) * 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
AU9149791A (en) * 1990-12-06 1992-07-08 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
DE69328098T2 (de) * 1992-06-24 2000-08-24 Adprotech Plc Lösliche derivate des complement type-rezeptors (cr1)
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
CA2155933C (en) * 1993-02-12 2000-04-04 James L. Levin Pulmonary administration of scr1 and other complement inhibitory proteins
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9706950D0 (en) * 1997-04-05 1997-05-21 Chernajovsky Yuti Immune modulation by polypeptides related to CR1
AU5317499A (en) * 1998-07-24 2000-02-14 Uab Research Foundation Genetic polymorphism in a complement receptor
US6664052B1 (en) 1998-07-24 2003-12-16 The Uab Research Foundation Genetic polymorphism in a complement receptor
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
WO2010047793A2 (en) 2008-10-21 2010-04-29 The General Hospital Corporation Cell transplantation
EP2601299B1 (en) 2010-08-06 2019-04-24 The General Hospital Corporation D/B/A Massachusetts General Hospital System and apparatus for cell treatment
CN107661491A (zh) 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
AU2011332241B2 (en) 2010-11-02 2015-11-26 Kypha, Inc. Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
CN102702339B (zh) * 2011-05-24 2013-10-30 华南师范大学 斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用
CN104159926B (zh) * 2011-12-01 2019-02-01 圆祥生命科技有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104293836A (zh) * 2014-06-24 2015-01-21 长沙赢润生物技术有限公司 一种免疫复合物吸附细胞的制作方法
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3760645A1 (en) * 2019-07-02 2021-01-06 imusyn GmbH & Co. KG Analysis for blood group antigen dacy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192948A (ja) * 1984-03-14 1985-10-01 Fuji Photo Film Co Ltd 湿し水不要ネガ型感光性平版印刷版および製版方法
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)

Also Published As

Publication number Publication date
DK234890D0 (da) 1990-09-28
IL89790A (en) 2002-05-23
ZA907693B (en) 1992-05-27
FI115528B (fi) 2005-05-31
JP3484189B2 (ja) 2004-01-06
ATE240973T1 (de) 2003-06-15
WO1989009220A1 (en) 1989-10-05
CN1053265A (zh) 1991-07-24
EP0411031A4 (en) 1992-02-05
IL89790A0 (en) 1989-09-28
DE68929466T2 (de) 2004-04-01
NO20000827L (no) 1990-11-09
CN1053924C (zh) 2000-06-28
ZA892397B (en) 1989-11-29
EP0411031B1 (en) 2003-05-21
CA1341443C (en) 2003-10-07
FI20002515A (fi) 2000-11-16
EP0411031A1 (en) 1991-02-06
AU3539489A (en) 1989-10-16
FI904842A0 (fi) 1990-10-01
CN1036987A (zh) 1989-11-08
JPH04501502A (ja) 1992-03-19
AU647371B2 (en) 1994-03-24
CN1092712C (zh) 2002-10-16
ES2014593A6 (es) 1990-07-16
NO315944B1 (no) 2003-11-17
DK175699B1 (da) 2005-01-24
CA1340866C (en) 1999-12-28
NO20000827D0 (no) 2000-02-18
DE68929466D1 (de) 2003-06-26
DK234890A (da) 1990-11-30
FI106316B (fi) 2001-01-15

Similar Documents

Publication Publication Date Title
EP0502892A4 (en) The human c3b/c4b receptor (cr1)
ZA907693B (en) The human c3b/c4b receptor(cr1)
Seidman et al. The structure of rat preproatrial natriuretic factor as defined by a complementary DNA clone
US5401651A (en) DNA encoding ENA-78, a neutrophil activating factor
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
CA2529179A1 (en) Recombinant adeno-associated virus vector for treatment of alzheimer disease
HUT77578A (hu) A 10-es számú fibroblaszt növekedési faktor (FGF-10)
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
Dewji et al. Nucleotide sequence of cloned cDNA for human sphingolipid activator protein 1 precursor.
MX9203654A (es) Purificacion, clonacion y caracterizacion del gen para la interleucina i.
PT98695A (pt) Gene codificador do factor neurotrofico de ligacao a heparina
EP0913470A3 (en) The human C3b/C4b receptor (CR1)
KR930701475A (ko) 사람의 거핵구-집락 촉진 인자(hMeg-CSF) 및 그것의 생산방법
BR0208140A (pt) Polipeptìdeo, agente imunoterapêutico para o tratamento de psorìase, sequência de ácido nucléico isolada ou seu complemento, vetores de filamento único, e de filamento duplo, sequência de ácido nucléico isolada ou variante imunogênica da mesma, métodos para a produção de polipeptìdeos, e para o tratamento e a remissão clìnica de psorìase, e, célula hospedeira microbiana
EP0308424A1 (en) A novel protein, neuroleukin
EP0341100A2 (en) DNA coding for thymosin and TNF
WO1998004692A3 (en) Human neuronatin
JPH07309778A (ja) 創傷治療剤